Loading
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
Approvals span melanoma, NSCLC, head and neck, Hodgkin, urothelial, MSI-H/dMMR tumours (first tumour-agnostic approval, 2017), gastric, oesophageal, cervical, HCC, RCC, endometrial, TNBC (KEYNOTE-355 metastatic CPS ≥10; KEYNOTE-522 neoadjuvant/adjuvant with 7-year OS benefit), TMB-high, and more. 2026 additions include platinum-resistant PD-L1+ ovarian cancer, adjuvant RCC with belzutifan, and combination labels with sacituzumab govitecan (ASCENT-04) and enfortumab vedotin. Subcutaneous Keytruda Qlex approved 2025. Backbone for neoantigen vaccines (intismeran).
Backbone ribbon from PDB 5DK3. RCSB PDB 5DK3. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Humanised IgG4 blocking PD-1; restores T-cell effector function. Connects to PD-1.
1.Antibody binds PD-1 on T cells
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. HCPCS J9271. The subcutaneous Keytruda Qlex is also clinician-administered and stays in Part B.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. The largest-selling cancer drug in the US; nearly every plan has a Keytruda policy tied to indication and PD-L1 status where the label requires it.
Merck, KEYTRUDA cost and financial support page (2024). Net prices after rebates are usually lower.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA531 · SMC advice: pembrolizumab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
The largest loss of exclusivity in oncology history by revenue. Merck's subcutaneous formulation and new indications are the life-cycle defence.
The first head-to-head test of the PD-1 x VEGF bispecific against pembrolizumab in a Western population. Timing is our estimate from the registry record; the sponsor has not given a date. Source
Phase 3 in first-line KRAS G12C-mutant NSCLC. Timing is a registry-based estimate. Source
The sponsors said filings would follow the positive topline result of August 2026 and the full data presentation. Timing is our estimate. Source
Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
Accelerated approval, advanced melanoma after ipilimumab; first PD-1 inhibitor in the US source
Metastatic PD-L1 positive NSCLC, as determined by an FDA-approved test, with progression on or after platinum-containing chemotherapy
PD-L1+ NSCLC after platinum source
Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
Confirmed: the accelerated approval of 2014 converted to traditional approval 1.3 years after it was granted.
Recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Metastatic PD-L1 positive NSCLC, as determined by an FDA-approved test, with progression on or after platinum-containing chemotherapy
Confirmed: the accelerated approval of 2015 converted to traditional approval 1.1 years after it was granted.
Adult and pediatric patients with refractory classical Hodgkin Lymphoma or who have relapsed after 3 or more prior lines of therapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
In combination with pemetrexed and carboplatin for first-line treatment of metastatic non-squamous NSCLC
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy 1
Accelerated approval on a surrogate endpoint, with a confirmatory trial required. source
Treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or metastatic MSI-H or dMMR colorectal cancer that have progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan
MSI-H/dMMR solid tumours: first tumour-agnostic approval source
For patients with recurrent or locally advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1 [CPS ≥1] as determined by an FDA-approved test, with disease progression on/after two or more prior lines of therapy including fluoropyrimidine and platinum containing chemotherapy and if appropriate, HER2/NEU targeted therapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after 2 or more prior lines of therapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
In combination with pemetrexed and carboplatin for first-line treatment of metastatic non-squamous NSCLC
Confirmed: the accelerated approval of 2017 converted to traditional approval 1.3 years after it was granted.
Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Accelerated approval on a surrogate endpoint, with a confirmatory trial required. source
Treatment of adults and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
Accelerated approval on a surrogate endpoint, with a confirmatory trial required. source
Recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy
Confirmed: the accelerated approval of 2016 converted to traditional approval 2.8 years after it was granted.
Metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with melanoma, hepatocellular carcinoma, Merkel cell carcinoma, gastric cancer, non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, cervical carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, small cell lung cancer, esophageal cancer, microsatellite instability-high or mismatch repair deficient solid tumors
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Dosing Regimen: Alternative dose/schedule of 400 mg every 6 weeks for adult patients with classical Hodgkin lymphoma and primary mediastinal b-cell lymphoma
Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 6.4 years later, when the FDA's table was read.
Treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden high (TMB H) [=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options .
TMB-high solid tumours (tumour-agnostic) The confirmatory requirement was still open 6.3 years later, when the FDA's table was read. source
Dosing Regimen: Alternate Dose/Schedule of 400 mg every 6 weeks for adult patients with unresectable or metastatic tumor mutational burden high [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with cutaneous squamous cell carcinoma
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Adult and pediatric patients with refractory classical Hodgkin Lymphoma or who have relapsed after 3 or more prior lines of therapy
Confirmed: the accelerated approval of 2017 converted to traditional approval 3.6 years after it was granted.
Adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after 2 or more prior lines of therapy
Confirmed: the accelerated approval of 2018 converted to traditional approval 2.3 years after it was granted.
In combination with chemotherapy for locally recurrent unresectable or metastatic TNBC expressing PD L1 [CPS =10] as determined by an FDA-approved test
Metastatic TNBC, PD-L1 CPS ≥10, with chemotherapy (KEYNOTE-355) source
Metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy
Withdrawn: the indication came off the label 1.8 years after its accelerated approval.
In combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma 1
Accelerated approval on a surrogate endpoint, with a confirmatory trial required. source
In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
Confirmed: the accelerated approval of 2019 converted to traditional approval 1.8 years after it was granted.
In combination with chemotherapy for locally recurrent unresectable or metastatic TNBC expressing PD L1 [CPS =10] as determined by an FDA-approved test
High-risk early TNBC, neoadjuvant and adjuvant (KEYNOTE-522) source
Locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy 1
Confirmed: the accelerated approval of 2017 converted to traditional approval 4.3 years after it was granted. source
Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test
Confirmed: the accelerated approval of 2018 converted to traditional approval 3.3 years after it was granted.
For patients with recurrent or locally advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1 [CPS ≥1] as determined by an FDA-approved test, with disease progression on/after two or more prior lines of therapy including fluoropyrimidine and platinum containing chemotherapy and if appropriate, HER2/NEU targeted therapy
Withdrawn: the indication came off the label 4.4 years after its accelerated approval.
Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with melanoma, hepatocellular carcinoma, Merkel cell carcinoma, gastric cancer, non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, cervical carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, small cell lung cancer, esophageal cancer, microsatellite instability-high or mismatch repair deficient solid tumors
Confirmed: the accelerated approval of 2020 converted to traditional approval 2.6 years after it was granted.
Dosing Regimen: Alternate Dose/Schedule of 400 mg every 6 weeks for adult patients with unresectable or metastatic tumor mutational burden high [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options
Confirmed: the accelerated approval of 2020 converted to traditional approval 2.5 years after it was granted.
Dosing Regimen: Alternative dose/schedule of 400mg every 6 weeks for adult patients with cutaneous squamous cell carcinoma
Confirmed: the accelerated approval of 2020 converted to traditional approval 2.5 years after it was granted.
Treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or metastatic MSI-H or dMMR colorectal cancer that have progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan
Confirmed: the accelerated approval of 2017 converted to traditional approval 5.8 years after it was granted.
In combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required. source
Treatment of adults and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
Confirmed: the accelerated approval of 2018 converted to traditional approval 4.8 years after it was granted. source
Perioperative NSCLC (KEYNOTE-671) source
In combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy
Confirmed: the accelerated approval of 2023 converted to traditional approval 0.7 years after it was granted. source
Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Confirmed: the accelerated approval of 2018 converted to traditional approval 5.2 years after it was granted. source
In combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma 1
Confirmed: the accelerated approval of 2021 converted to traditional approval 3.9 years after it was granted. source
Subcutaneous pembrolizumab (Keytruda Qlex) source
Formulation: Treatment of adult and pediatric patients 12 years and older with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options .
Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 1.0 year later, when the FDA's table was read. source
Platinum-resistant PD-L1+ ovarian cancer source
Adjuvant RCC with belzutifan (LITESPARK-022) source
First-line PD-L1+ TNBC with sacituzumab govitecan (ASCENT-04) source
Muscle-invasive bladder cancer with enfortumab vedotin, as pembrolizumab or pembrolizumab with berahyaluronidase alfa source
| Region | Year | Indication |
|---|---|---|
| US | 2014 | Melanoma (first of >40 indications) |
| US | 2017 | MSI-H/dMMR solid tumours (tumour-agnostic) |
| US | 2020 | Metastatic TNBC, PD-L1 CPS ≥10, with chemotherapy |
| US | 2021 | High-risk early TNBC, neoadjuvant + adjuvant (KEYNOTE-522) |
| US | 2023 | Locally advanced unresectable or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (KEYNOTE-966) · Keytruda label (openFDA), KEYNOTE-966 section: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22KEYTRUDA%22; no NICE appraisal for biliary tract cancer found in September 2026 |
| US | 2026 | Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC |
| EU | 2021 | Locally recurrent unresectable or metastatic TNBC, PD-L1 CPS 10 or more, with chemotherapy, no prior chemotherapy for metastatic disease (KEYNOTE-355) · EMA Keytruda product page, therapeutic indications: https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda |
| EU | 2022 | Locally advanced or early-stage TNBC at high risk of recurrence: neoadjuvant with chemotherapy, then adjuvant monotherapy (KEYNOTE-522) · EMA Keytruda product page: https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda |
| UK | 2022 | Untreated triple-negative locally recurrent unresectable or metastatic breast cancer with paclitaxel or nab-paclitaxel; NICE TA801 (29 June 2022) recommends it only for tumours with CPS 10 or more and immune-cell staining below 1 percent (the atezolizumab population is carved out), under a commercial arrangement · https://www.nice.org.uk/guidance/ta801 |
| UK | 2022 | Neoadjuvant with chemotherapy then adjuvant alone for triple-negative early breast cancer at high risk of recurrence or locally advanced disease; NICE TA851 (14 December 2022) recommends within the marketing authorisation, routine commissioning with a commercial arrangement · https://www.nice.org.uk/guidance/ta851 |
| UK | 2023 | Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer · https://www.nice.org.uk/guidance/ta914 |
| England (NICE) | 2021 | Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency · TA709, published 23 June 2021: recommended only if pembrolizumab is stopped after two years without documented progression and the company provides it under the commercial arrangement. |
| England (NICE) | 2023 | Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer · TA914, published 20 September 2023: in colorectal cancer after fluoropyrimidine combination therapy, only if nivolumab with ipilimumab is unsuitable, and stopped at two years. |
| England (NICE) | 2018 | Untreated PD-L1-positive metastatic non-small-cell lung cancer with a tumour proportion score of 50 percent or more and no EGFR or ALK alteration · TA531, published 18 July 2018, only if pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier on progression. |
| England (NICE) | 2021 | Untreated metastatic non-squamous non-small-cell lung cancer without an EGFR or ALK alteration, with pemetrexed and platinum chemotherapy · TA683, published 10 March 2021, only if stopped at 2 years of uninterrupted treatment or earlier on progression. |
| England (NICE) | 2022 | Untreated metastatic squamous non-small-cell lung cancer, with carboplatin and paclitaxel · TA770, published 9 February 2022, for a tumour proportion score of 0 to 49 percent, or 50 percent or more where urgent clinical intervention is needed, stopped at 2 years. |
| England (NICE) | 2017 | Locally advanced or metastatic PD-L1-positive non-small-cell lung cancer after at least one chemotherapy · TA428, published 11 January 2017 and last updated 12 September 2017, stopped at 2 years of uninterrupted treatment. |
| England (NICE) | 2024 | Resectable non-small-cell lung cancer at high risk of recurrence, neoadjuvant with platinum chemotherapy then adjuvant alone · TA1017, published 20 November 2024 (KEYNOTE-671), subject to the commercial arrangement. |
| England (NICE) | 2025 | Adjuvant treatment of non-small-cell lung cancer at high risk of recurrence after complete resection and platinum chemotherapy · TA1037, published 5 February 2025 (KEYNOTE-091), subject to the commercial arrangement. |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Hypothyroidism (immune-mediated) | 8% | - |
| Pneumonitis (immune-mediated) | 3.4% | - |
| Colitis (immune-mediated) | 1.7% | - |
| Hepatitis (immune-mediated) | 0.7% | - |
| Fatigue | - | - |
| Musculoskeletal pain | - | - |
| Rash | - | - |
| Diarrhoea | - | - |
| Pyrexia | - | - |
Pooled monotherapy data, >2,800 patients. Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (immune checkpoint inhibitors) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part B (physician-administered); commercial plans per formulary | $11,564 per 200 mg dose (WAC, Merck price disclosure 2024) | merckaccessprogram-keytruda.com |
| United Kingdom | NICE: recommended across many indications (melanoma, NSCLC, TNBC KEYNOTE-522/355, RCC, HNSCC, cervical, oesophageal and others) | not disclosed | - |
| European Union | EMA approved; reimbursed in all member states for core indications | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
The 48 most recent of 60 papers; see them all →
For the first time a new drug has beaten pembrolizumab, the global first-line standard, in a randomised lung cancer trial, and it did so by combining checkpoint blockade with anti-angiogenesis in one molecule. For patients outside China nothing changes yet: the drug is not approved in the West, the trial was single-country, and survival benefit has not been shown. If confirmed in the global HARMONi-3 and HARMONi-7 trials, PD-1 x VEGF bispecifics could replace PD-1 antibodies as the immunotherapy backbone.
Perioperative pembrolizumab is a new standard for resectable head and neck cancer with PD-L1 expression, adding immunotherapy to a treatment pathway that had not changed since postoperative chemoradiation was defined.
Lenvatinib-pembrolizumab with chemoembolisation is an emerging option for intermediate-stage disease, balanced against substantial toxicity.
Platinum and immunotherapy are now consensus for early triple-negative disease; the open votes have moved to who can safely receive less.
Almost every patient newly diagnosed with advanced bladder or urothelial cancer should now be offered enfortumab vedotin plus pembrolizumab rather than chemotherapy, with median survival extended from about 16 months to over two and a half years. Neuropathy and skin toxicity need monitoring and dose adjustment, and patients with severe diabetes or pre-existing neuropathy need care. Platinum chemotherapy remains an option for those who cannot receive the combination.
For the first time a randomised trial suggests that a vaccine tailored to an individual's tumour can reduce relapse when combined with immunotherapy, which is a proof of concept for a field that had failed for decades. Nothing changes for patients yet: the trial was small, the confidence interval crossed one, and the phase 3 trial in melanoma (and parallel trials in lung and other cancers) must confirm it. If it does, personalised mRNA vaccines could become a routine adjunct to checkpoint inhibitors after surgery.
The survival gain turns the earlier progression-free survival result into a clear reason to offer pembrolizumab with and after chemoradiotherapy to women with node-positive or stage III-IVA cervical cancer. Because cervical cancer is concentrated in low- and middle-income countries, the benefit reaches most women only if pricing and access follow.
Women with locally advanced cervical cancer that is node-positive or stage III-IVA can be offered pembrolizumab alongside and after chemoradiotherapy to lower the chance of relapse. The result matters most in countries where cervical cancer is common but immunotherapy access is poorest, so its global impact depends on pricing and health-system capacity. It does not apply to early-stage disease treated with surgery or to lower-risk locally advanced disease without nodal involvement.
Query for this drug: (TITLE:"Pembrolizumab" OR ABSTRACT:"Pembrolizumab" OR TITLE:"Keytruda" OR ABSTRACT:"Keytruda" OR TITLE:"Keytruda Qlex" OR ABSTRACT:"Keytruda Qlex") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pembrolizumab, not a curated reading list.
Shares Automatic price cuts when a cancer drug's approved indications and volumes expand, Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors, A Phase 1/2 Study of BA3071 in Patients With Solid Tumors, A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors.
Shares A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors, A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors, A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer, A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC.
Shares Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors, A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation, Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC, FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease.
Shares A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors, Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer, A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s, A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung.
Shares Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC, A Phase 1/2 Study of BA3071 in Patients With Solid Tumors, Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors, Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy .
Shares ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer, Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC, A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s.
Shares Arjun V. Balar, KEYNOTE-170, KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer, PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer).
Shares A Study in Patients With Advanced Cancers, A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca, NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III), Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC.